Avid is the leader in development of molecular imaging agents with multiple promising commericial PET compounds already in clinical trials in disease states with significant unmet clinical need (Alzheimer's disease, Parkinson's disease and diabetes). Avid has also established imaging collaborations with multiple big pharma partners. Avid has certain preferred rights for negotiation of additional licenses to compounds through its support of research at the University of Pennsylvania, University of Michigan, Columbia University, and other universities.

Strategy: Avid is focused on developing molecular imaging agents with the potentilal for early diagnosis and prognosis of major chronic human diseases, such as AD, PD/DLB, and diabetes. The company has followed the FDA's exploratory IND guidance and subsequent FDA Advisory Committee recommendations on clinical development to rapidly test multiple compounds in clinical trials and bring forward only those molecular imaging agents that show the best utility. Avid is partnering with therapeutic drug developers in clinical trials in order to establish Avid's compounds as the standard biomarkers for pairing with therapeutics in the marketplace.